Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer

Clinical Cancer Research

Volumn 13, Issue 4, 2007, Pages 1123-1132

  Maurer, Gabriele D ^a   Leupold, Joerg H ^a   Schewe, Denis M ^b   Biller, Tobias ^a   Kates, Ronald E ^c   Hornung, Hans Martin ^b   Lau Werner, Ulla ^b   Post, Stefan ^a   Allgayer, Heike ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; UROKINASE RECEPTOR;

ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ASSAY; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE MUTATION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MOTIF;

COLORECTAL NEOPLASMS; FEMALE; GENES, RAS; GENES, SRC; HUMANS; MALE; MUTATION; PROGNOSIS; PROMOTER REGIONS (GENETICS); RECEPTORS, CELL SURFACE; SP1 TRANSCRIPTION FACTOR; SRC-FAMILY KINASES; SURVIVAL RATE; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 33947195421     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1668     Document Type: Article

References (50)

1. Lipponen P, Aaltomaa S, Kellokoski J, Ala-Opas M, Kosma V. Expression of activator protein 2 in prostate cancer is related to tumor differentiation and cell proliferation. Eur Urol 2000;37:573-8.
2. Anttila MA, Kellokoski JK, Moisio KI, et al. Expression of transcription factor AP-2alpha predicts survival in epithelial ovarian cancer. Br J Cancer 2000;82:1974-83.
3. Wang L, Wei D, Huang S, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 2003;9:6371-80.
4. Schewe DM, Leupold JH, Boyd DD, et al. Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers. Clin Cancer Res 2003;9:2267-76.
5. Schewe DM, Biller T, Maurer G, et al. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. Clin Cancer Res 2005;11:8538-48.
6. Ossowski L, Clunie G, Masucci MT, Blasi F. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 1991;115:1107-12.
7. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. BioEssays 1993;15:105-11.
8. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen-activators, tissue degradation, and cancer. Adv Cancer Res 1985;44:139-266.
9. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
10. Ploug M, Behrendt N, Lober D, Dano K. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Semin Thromb Hemost 1991;17:183-93.
11. Estreicher A, Muhlhauser J, Carpentier JL, Orci L, Vassalli JD. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990;111:783-92.
12. Allgayer H, Boyd DD, Lengyel ER, Heiss MM. The urokinase-receptor: molecular regulation and clinical significance. Adv Cancer Res 2001;1:85-97.
13. Moller LB. Structure and function of the urokinase receptor. Blood Coagul Fibrinolysis 1993;4:293-303.
14. Cantero D, Friess H, Deflorin J, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 1997;75:388-95.
15. Jankun J, Merrick HW, Goldblatt PJ. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem 1993;53:135-44.
16. Pedersen H, Grondahl-Hansen J, Francis D, et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 1994;54:120-3.
17. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990;50:6827-9.
18. Allgayer H, Heiss MM, Schildberg FW. Prognostic factors in gastric cancer: a review. Br J Surgery 1997;84:1651-64.
19. Nekarda H, Schmitt M, Ulm K, et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994;54:2900-7.
20. Heiss MM, Babic R, Allgayer H, et al. Tumor associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 1995;13:2084-93.
21. Janicke F, Schmitt M, Pache L, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node negative breast cancer. Breast Cancer Res Treat 1993;24:195-208.
22. Ganesh S, Sier CFM, Heerding MM, Griffionen G, Lamers CBH, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet 1994;344:401-2.
23. Wang H, Skibber J, Juarez J, Boyd D. Transcriptional activation of the urokinase receptor gene in invasive colon cancer. Int J Cancer 1994;58:650-7.
24. Shetty S, Kumar A, Idell S. Posttranscriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Mol Cell Biol 1997;17:1075-83.
25. Gum R, Juarez J, Allgayer H, Mazar A, Wang Y, Boyd D. Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires a JNK1-dependent signalling molecule. Oncogene 1998;17:213-25.
26. Wang H, Yang L, Jamaluddin M, Boyd D. The Kruppel-like KLF4 transcription factor, a novel regulator of urokinase receptor expression, drives synthesis of this binding site in colonic crypt luminal surface epithelial cells. J Biol Chem 2004;279:22674-83.
27. Allgayer H, Wang H, Wang Y, et al. Transcription of the urokinase-type plasminogen activator receptor gene through a novel promotor motif bound with an activator protein-2alpha-related factor. J Biol Chem 1999;274:4702-14.
28. Allgayer H, Wang H, Gallick GE, et al. Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1. J Biol Chem 1999;274:18428-37.
29. Allgayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002;94:344-51.
30. Lengyel E, Wang H, Stepp E, et al. Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J Biol Chem 1996;271:23176-84.
31. Lengyel E, Wang H, Gum R, Simon C, Wang Y, Boyd D. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signalling cascade. Oncogene 1997;14:2563-73.
32. Allgayer H, Wang H, Shirasawa S, Sasazuki T, Boyd D. Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis. Br J Cancer 1999;80:1884-91.
33. Heiss MM, Allgayer H, Gruetzner KU, Babic R, Jauch KW, Schildberg FW. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Ann Surg 1997;226:736-45.
34. Leupold JH, Lengyel E, Post S, Allgayer H. Src-induced u-PAR gene expression is also mediated via an AP-1 motif and is associated with increased invasive capacity in vivo [abstract]. Proceedings of the American Association for Cancer Research (AACR) 2005;46:4526.
35. Mulcahy H, Duffy M, Gibbons D, et al. Urokinase-type plasminogen activator and outcome in Dukes B colorectal cancer. Lancet 1994;344:583-4.
36. Silva D, English D, Lyons D, Lloyd F, Jr. Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB. Biochem Biophys Res Commun 2002;290:552-7.
37. Milde-Langosch K, Roder H, Andritzky B, et al. The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas. Breast Cancer Res Treat 2004;86:139-52.
38. Hahm E, Gho Y, Park S, Park C, Kim K, Yang C. Synthetic curcumin analogs inhibit activator protein-1 transcription and tumor-induced angiogenesis. Biochem Biophys Res Commun 2004;321:337-44.
39. Heiss MM, Babic R, Allgayer H, et al. The prognostic impact of the urokinase type plasminogen activator system is associated with tumour differentiation in gastric cancer. Eur J Surg Oncol 1996;22:74-7.
40. Heimberger AB, McGary EC, Suki D, et al. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res 2005;11:267-72.
41. Friedrichs N, Jager R, Paggen E, et al. Distinct spatial expression patterns of AP-2alpha and AP-2gamma in non-neoplastic human breast and breast cancer. Mod Pathol 2005;18:431-8.
42. Assimakopoulou M, Varakis J. AP-1 and heat shock protein 27 expression in human astrocytomas. J Cancer Res Clin Oncol 2001;127:727-32.
43. Papachristou D, Batistatou A, Sykiotis G, Varakis I, Papavassiliou A. Activation of the JNK-AP-1 signal transduction pathway is associated with pathogenesis and progression of human osteosarcomas. Bone 2003;32:364-71.
44. Karamouzis M, Sotiropoulou-Bonikou G, Vandoros G, Varakis I, Papavassiliou A. Differential expression of retinoic acid receptor beta (RARbeta) and the AP-1 transcription factor in normal, premalignant and malignant human laryngeal tissues. Eur J Cancer 2004;40:761-73.
45. Lewin B. Genes VII. 2000. New York: Oxford University Press: chapters 9 and 26.
46. Boulikas T. Control of DNA replication by protein phosphorylation. Anticancer Res 1994;14:2465-72.
47. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995;270:16483-6.
48. Zoumpourlis V, Papassava P, Linardopoulos S, Gillespie D, Balmain A, Pintzas A. High levels of phosphorylated c-Jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model. Oncogene 2000;19:4011-21.
49. Li L, He S, Sun JM, Davie JR. Gene regulation by Sp1 and Sp3. Biochem Cell Biol 2004;82:460-71.
50. Besch R, Giovannangeli C, Kammerbauer C, Degitz K. Specific inhibition of ICAM-1 expression mediated by gene targeting with Triplex-forming oligonucleotides. J Biol Chem 2002;277:32473-9.